Anthem Biosciences Ltd Upgraded to Hold on Technical and Financial Reassessment

Technical Trends Shift to Mildly Bullish

The most significant catalyst for the upgrade stems from a positive change in Anthem Biosciences’ technical outlook. Previously characterised by a sideways trend, the technical grade has now shifted to mildly bullish on a weekly basis. Key technical indicators such as the Moving Average Convergence Divergence (MACD) and On-Balance Volume (OBV) on a weekly scale have shown encouraging signs, with OBV indicating mild buying pressure. The Dow Theory also supports this mild bullishness weekly, although monthly trends remain neutral.

Despite the stock’s recent one-day decline of 3.58%, the technical momentum suggests a potential stabilisation and gradual upward movement. The stock price currently trades at ₹662.05, down from the previous close of ₹686.65, but remains comfortably above its 52-week low of ₹579.45. The 52-week high stands at ₹873.25, indicating room for recovery should technical strength persist.

Valuation Remains Expensive but Justified by Growth

Anthem Biosciences’ valuation remains on the higher side, with a Price to Book (P/B) ratio of 13, which is considered very expensive relative to industry peers. This elevated valuation is supported by a strong Return on Equity (ROE) of 19.93%, reflecting efficient capital utilisation by management. The company’s market capitalisation grade is rated 2, indicating a moderate size in the Pharmaceuticals & Biotechnology sector.

While the stock has underperformed the Sensex over the past year, generating a flat return of 0.00% compared to the Sensex’s 8.39% gain, Anthem’s profits have risen by 35% in the same period. This divergence suggests that the market may be pricing in near-term risks despite solid earnings growth. Investors should weigh the premium valuation against the company’s demonstrated ability to deliver consistent profitability improvements.

Financial Trend: Mixed Quarterly Results but Strong Long-Term Growth

Anthem Biosciences reported a disappointing Q3 FY25-26 with Profit Before Tax (PBT) excluding other income falling 24.2% to ₹122.31 crores compared to the previous four-quarter average. Similarly, Profit After Tax (PAT) declined 14.1% to ₹110.87 crores, and net sales hit a quarterly low of ₹423.15 crores. These results have weighed on short-term sentiment and contributed to the stock’s recent volatility.

However, the company’s long-term financial trajectory remains robust. Net sales have grown at an annualised rate of 29.80%, while operating profit has expanded even faster at 44.32% per annum. The company maintains a debt-to-equity ratio averaging zero, underscoring a conservative capital structure that reduces financial risk. High management efficiency is evident in the ROE of 19.93%, signalling effective utilisation of equity capital despite recent earnings softness.

Quality Assessment: Promoter Control and Operational Strength

Anthem Biosciences benefits from a stable ownership structure with promoters holding the majority stake, which often aligns management incentives with shareholder interests. The company’s quality grade remains solid, supported by consistent operational execution and a strong balance sheet. Despite the recent quarterly earnings dip, the underlying business model and sector fundamentals in Pharmaceuticals & Biotechnology remain favourable.

Comparatively, the company’s Mojo Score stands at 50.0 with a Mojo Grade of Hold, upgraded from Sell on 4 March 2026. This reflects a balanced view acknowledging both the risks from recent earnings weakness and the positives from technical improvements and long-term growth potential.

Stock Performance Relative to Market Benchmarks

Over the past week, Anthem Biosciences’ stock has declined 5.91%, underperforming the Sensex’s 3.84% fall. However, the one-month return is a robust 9.46%, significantly outperforming the Sensex’s negative 5.61% return. Year-to-date, the stock has gained 1.69%, while the Sensex is down 7.16%. These mixed returns highlight the stock’s volatility but also its capacity for short-term rebounds amid broader market weakness.

Longer-term returns are not available for the stock, but the Sensex’s 10-year return of 221.00% provides context for the sector’s growth potential. Anthem’s strong sales and profit growth rates suggest it could capture a meaningful share of this market expansion if it sustains operational momentum.

Outlook and Investor Considerations

Investors should approach Anthem Biosciences with a balanced perspective. The upgrade to Hold reflects improved technical signals and solid long-term fundamentals, but the recent quarterly earnings decline and expensive valuation warrant caution. The company’s zero debt position and high ROE provide a strong foundation, yet the stock’s underperformance relative to the Sensex over the past year indicates market scepticism.

Given the mildly bullish technical trend and healthy growth rates, the stock may offer upside potential if it can return to consistent profitability and justify its premium valuation. However, investors should monitor upcoming quarterly results closely for signs of recovery or further deterioration.

Overall, Anthem Biosciences remains a stock for investors favouring quality pharmaceutical companies with strong management and growth prospects, but with a need for patience amid near-term volatility.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →